Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality

Table 3 Comparison between liver enzymes, acute liver injury, chronic liver disease, and fibrosis score between patients with and without hepatitis C virus, n (%)

	All (n = 1065)	ALI patients (n = 1065)			Propensity score matched (n = 81)
		No HCV (n = 1014)	HCV (n = 41)	P value	No HCV (n = 40)	HCV (n = 41)	P value
AST/ALT	1.88 ± 1.5	1.86 ± 1.5	2.4 ± 1.3	0.023	1.8 ± 0.88	2.4 ± 1.27	0.015
Any liver enzyme elevated	639 (60)	610 (60)	29 (71)	0.174	25 (63)	29 (71)	0.423
Normal liver enzymes	416 (39)	311 (31)	10 (24)	0.242	15 (38)	10 (24)	0.223
Only ALT elevated	6 (1)	6 (1)	0 (0)		0 (0)	0 (0)
Only AST elevated	432 (41)	409 (40)	23 (56)		15 (38)	2356
Both elevated	201 (19)	195 (19)	6 (15)		10 (25)	6 (15)
AST > ALT	423 (40)	399 (39)	20 (49)	0.394			0.394
All AST > ALT	633 (59)	604 (60)	29 (71)	0.153	25 (63)	29 (71)	0.423
Fatty liver	50 (5)	48 (5)	2 (5)	0.931	1 (3)	2 (5)	0.582
History of cirrhosis	6 (1)	5 (1)	1 (2)	0.228	2 (5)	1 ()	0.534
Fib-4 score	3.43 ± 5.5	3.47 ± 5.6	3.1 ± 3.6	0.642	3.4 ± 2.25	3.1 ± 3.6	0.249
ALI1	107 (10)	100 (10)	7 (17)	0.128	3 (8)	7 (17)	0.166

¹Acute liver injury; defined as any of the following criteria: Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevated 2 times above the upper normal; and Limit or any of AST or ALT elevated 2 times above the upper normal level, and at least one of the following: Elevated combined bilirubin, total bilirubin or elevated PT more than 2 times the normal limit. HCV: Hepatitis C virus; ALI: Acute liver injury AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.